Latest Conference Articles

Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community.

Recent research suggests amblyopia has an affect on binocular vision

Recent research suggests amblyopia has an affect on binocular vision

May 13th 2022

ARVO

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

Study: Keratoconus patients experience challenges in getting timely corneal crosslinking that has led to permanent changes in their corneal structure

Study: Keratoconus patients experience challenges in getting timely corneal crosslinking that has led to permanent changes in their corneal structure

May 13th 2022

ARVO

The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.

RNA-Seq analysis identifies cell subtypes to use as models for corneal wound healing

RNA-Seq analysis identifies cell subtypes to use as models for corneal wound healing

May 12th 2022

ARVO

At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.

Phase 3 PEACHTREE, AZALEA integrated study results presented at ARVO 2022: BCVA gains, CST reduction with Xipere

Phase 3 PEACHTREE, AZALEA integrated study results presented at ARVO 2022: BCVA gains, CST reduction with Xipere

May 12th 2022

ARVO

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.

Use of CO-02 to stimulate the trigeminal nerve is a reasonable mechanism to help treat dry eyes

Use of CO-02 to stimulate the trigeminal nerve is a reasonable mechanism to help treat dry eyes

May 11th 2022

ARVO

The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.

New advancements in IOL technology is exciting for presbyopia treatment

New advancements in IOL technology is exciting for presbyopia treatment

May 11th 2022

ASCRS

Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.

ARMOR study evaluates antibiotic resistance in the treatment of staph infections

ARMOR study evaluates antibiotic resistance in the treatment of staph infections

May 11th 2022

ARVO

Penny Asbell, MD, FACS, MBA, discusses “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."

Study evaluates OC-01 (varenicline solution) as a treatment for symptoms and signs of dry eye

Study evaluates OC-01 (varenicline solution) as a treatment for symptoms and signs of dry eye

May 11th 2022

ARVO

Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.

Cell therapy trial shows promising results for patients with advanced dry AMD

Cell therapy trial shows promising results for patients with advanced dry AMD

May 10th 2022

ARVO

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

New PRO instrument helps measure patient experience with therapies such as anti-VEGF agents, lasers to treat their eye disease

New PRO instrument helps measure patient experience with therapies such as anti-VEGF agents, lasers to treat their eye disease

May 9th 2022

ARVO

Diana Do, MD, professor of ophthalmology at Stanford's Byers Eye Institute, presents research on a newly developed, novel patient-reported outcome instrument (PRO) for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.